ENTITY
YiChang HEC ChangJiang Pharmaceutical

YiChang HEC ChangJiang Pharmaceutical (1558 HK)

137
Analysis
Health Care • China
YiChang HEC ChangJiang Pharmaceutical develops, manufactures, and sells pharmaceutical products, focusing on anti-viral, endocrine and metabolic, and cardiovascular diseases. Key products include Kewei (oseltamivir phosphate), Oumeining (telmisartan), and Ertongshu (benzbromarone). The company was founded in 2001 and is headquartered in Dongguan, China.
more
bullish•China Tower
•14 Jan 2019 14:50

HK Connect Discovery Weekly: China Tower, Tencent, New China Life (2019-01-11)

In our Discover HK Connect series, we aim to help our investors understand the flow of southbound trades via the Hong Kong Connect, as analyzed by...

Logo
714 Views
Share
•02 Jan 2019 15:09

Discover HK Connect: Mainlanders Were Buying Pharma and Property Managers in December

In our Discover HK Connect series, we aim to help our investors understand the flow of southbound trades via the Hong Kong Connect, as analyzed by...

Logo
837 Views
Share
•15 Oct 2018 14:11

Quiddity Weekly H/​​A: Share Spreads & Southbound Flows [Week to 12 Oct 2018]

This insight is an H/A Spread Monitor Project offering a brief look at recent changes in H-Share/A-Share spreads, Southbound flow and impact, and...

Logo
547 Views
Share
•24 Jul 2018 15:19

China Shineway(2877: HK): Beneficiary from Deregulation of Non-Essential Drug in Grassroots Level

A year ago, I wrote about China Shineway Pharmaceutical Group Ltd. (2877 HK) that has a couple of low-cost drugs that sell in the second and third...

Logo
657 Views
Share
•31 Oct 2016 09:52

TaiGen Sold Its Furaprevir for 25x of Market Capital

Summary What's new? Taigen and HEC Pharm announced a new joint venture.  HEC Pharm agrees Taigen to use its developed new drug Furaprevir...

Logo
481 Views
Share
x